CLINICAL TRIALS PROFILE FOR ENHERTU
✉ Email this page to a colleague
All Clinical Trials for ENHERTU
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03523572 ↗ | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | Active, not recruiting | AstraZeneca | Phase 1 | 2018-06-20 | This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens. Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab. The study will be done in two parts: - Part 1 is to identify the recommended dose to use for treatment. - Part 2 is to find out how well the combination works, and how safe and tolerable it is. |
| NCT03523572 ↗ | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | Active, not recruiting | Bristol-Myers Squibb | Phase 1 | 2018-06-20 | This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens. Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab. The study will be done in two parts: - Part 1 is to identify the recommended dose to use for treatment. - Part 2 is to find out how well the combination works, and how safe and tolerable it is. |
| NCT03523572 ↗ | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | Active, not recruiting | Daiichi Sankyo, Inc. | Phase 1 | 2018-06-20 | This is a study of trastuzumab deruxtecan, which was approved by the FDA (in December 2019) for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens. Participants will receive this study drug along with a cancer drug, an immune checkpoint inhibitor, anti-PD1, called nivolumab. The study will be done in two parts: - Part 1 is to identify the recommended dose to use for treatment. - Part 2 is to find out how well the combination works, and how safe and tolerable it is. |
| NCT04553770 ↗ | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Recruiting | Daiichi Sankyo Co., Ltd. | Phase 2 | 2020-10-09 | This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ENHERTU
Condition Name
Clinical Trial Locations for ENHERTU
Trials by Country
Clinical Trial Progress for ENHERTU
Clinical Trial Phase
Clinical Trial Sponsors for ENHERTU
Sponsor Name
